Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding.
Adding proton pump inhibitors (PPIs) to endoscopic therapy has become the mainstay of treatment for peptic ulcer bleeding, with current consensus guidelines recommending high-dose intravenous (IV) PPI therapy (IV bolus followed by continuous therapy). However, whether or not high-dose PPI therapy is more effective than low-dose PPI therapy is still debated. Furthermore, maintaining pH ≥ 4 appears to prevent mucosal bleeding in patients with acute stress ulcers; thus, stress ulcer prophylaxis with acid-suppressing therapy has been increasingly recommended in intensive care units (ICUs). This review evaluates the evidence for the efficacy of IV pantoprazole, a PPI, in preventing ulcer rebleeding after endoscopic hemostasis, and in controlling gastric pH and protecting against upper gastrointestinal (GI) bleeding in high-risk ICU patients. The review concludes that IV pantoprazole provides an effective option in the treatment of upper GI bleeding, the prevention of rebleeding, and for the prophylaxis of acute bleeding stress ulcers.
Tygerberg Academic Hospital, Stellenbosch University, Ward C7B, Cape Town, South Africa.
Christo J
CJ
van Rensburg
Director, Freelance Writing Works: a division of Creative Ink Ltd, Queenstown 9348, New Zealand.
Susan
S
Cheer
pantoprazole; peptic ulcer bleeding (PUB); pharmacological treatment; proton pump inhibitor (PPI)